(0.29%) 5 114.66 points
(0.39%) 38 390 points
(0.34%) 15 982 points
(-1.63%) $82.48
(5.10%) $2.02
(0.31%) $2 354.40
(0.24%) $27.60
(4.01%) $959.05
(-0.20%) $0.933
(-0.34%) $10.99
(-0.53%) $0.796
(1.69%) $93.42
0.00% $ 182.50
Live Chart Being Loaded With Signals
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD)...
Stats | |
---|---|
Tagesvolumen | 3.00 |
Durchschnittsvolumen | 4.22M |
Marktkapitalisierung | 0.00 |
EPS | $0 ( 2021-07-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 59.23 |
ATR14 | $1.935 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-07-21 | Coughlin Christopher J | Sell | 42 347 | Common Stock, par value $.0001 per share |
2021-07-21 | Coughlin Christopher J | Sell | 2 294 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 706 | Option to Purchase Common Stock |
2021-07-21 | Coughlin Christopher J | Sell | 2 343 | Option to Purchase Common Stock |
2021-07-21 | Sarin Aradhana | Sell | 120 253 | Common Stock, par value $.0001 per share |
INSIDER POWER |
---|
0.00 |
Last 100 transactions |
Buy: 1 094 307 | Sell: 1 860 897 |
Volumen Korrelation
Alexion Pharmaceuticals, Korrelation
10 Am meisten positiv korreliert | |
---|---|
CREC | 0.977 |
LDHA | 0.976 |
PRSR | 0.976 |
MSDAU | 0.973 |
PWUP | 0.973 |
IXAQ | 0.972 |
CRZN | 0.972 |
IGTA | 0.97 |
VLAT | 0.97 |
AEAE | 0.969 |
10 Am meisten negativ korreliert | |
---|---|
FUV | -0.983 |
MESA | -0.979 |
MBIO | -0.979 |
JG | -0.977 |
MLKN | -0.975 |
RENT | -0.974 |
NXTC | -0.974 |
GERN | -0.974 |
ASRV | -0.973 |
CNTY | -0.973 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Alexion Pharmaceuticals, Korrelation - Währung/Rohstoff
Alexion Pharmaceuticals, Finanzdaten
Annual | 2020 |
Umsatz: | $6.07B |
Bruttogewinn: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2020 |
Umsatz: | $6.07B |
Bruttogewinn: | $5.52B (90.88 %) |
EPS: | $2.74 |
FY | 2019 |
Umsatz: | $4.99B |
Bruttogewinn: | $4.60B (92.10 %) |
EPS: | $10.77 |
FY | 2018 |
Umsatz: | $4.13B |
Bruttogewinn: | $3.76B (90.94 %) |
EPS: | $0.348 |
Financial Reports:
No articles found.
Alexion Pharmaceuticals,
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.